Salvianolic acid B (SAB) has a high concentration in the liver, but the mechanism of its distribution in the liver is unclear. The aim of this study was to investigate the mechanisms of hepatic uptake of SAB. In this study, we first explored the uptake features of SAB in HepG2 cells and the effect of rifampicin on uptake. Then, we explored the effects of SAB on the uptake of pitavastatin in HepG2 cells. 
Salvianolic acid B (SAB) has a high concentration in the liver, but the mechanism of its distribution in the liver is unclear. The aim of this study was to investigate the mechanisms of hepatic uptake of SAB. In this study, we first explored the uptake features of SAB in HepG2 cells and the effect of rifampicin on uptake. Then, we explored the effects of SAB on the uptake of pitavastatin in HepG2 cells. Finally, we established an HEK239T-OATP1B1 cell model to confirm whether OATP1B1 mediated the transport of SAB. Results showed that the uptake kinetic parameters Vmax and Km for SAB in HepG2 cells were 21.28 ± 2.06 pmol mg −1 per protein min −1 and 28.47 ± 7.36 μM, respectively. Rifampicin inhibited the uptake of SAB in HepG2 cells (IC50 was 5.85 ± 1.70 μM), and SAB affected the uptake of pitavastatin in HepG2 cells (IC50 was 27.67 ± 1.90 μM). The uptake kinetic parameters Vmax and Km for SAB in HEK239T-OATP1B1 were 60.03 ± 6.16 pmol mg −1 per protein min −1 and 87.24 ± 15.28 μM, respectively, whereas in EGFP-HEK293 cells were 14.04 ± 2.53 pmol mg −1 per protein min −1 and 56.53 ± 15.50 μM. The SAB had no effect of on the expression of OATP1B1 in HEK239T-OATP1B1 cells. In conclusion, this study demonstrated that OATP1B1 contributes to the transport and accumulation of SAB in the liver.
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Salvianolic acid B (SAB), the major water-soluble component isolated from Salvia miltiorrhiza Bunge, has a wide spectrum of bioactivities, including protection of hepatocytes and hepatic stellate cells, antioxidant and antiatherosclerotic activities, inhibition of platelet aggregation, and alleviation of myocardial ischaemia-reperfusion injury (Liu et al., 2002; Shiao et al., 2008) . The oral absolute bioavailability of SAB is approximately 0.02%-5.56%. SAB has lower bioavailability because it mainly exists in the ionic state in the intestinal tract; this form cannot easily pass through the intestinal biofilm. After intragastric administration of SAB in rats, 65% of SAB was detected in gastrointestinal tract residues through which more than half of the drugs entered the colon (Zhang et al., 2004) .
The intestinal absorption mechanism of SAB is passive diffusion, but active transport or assisted diffusion may also participate in this intestinal absorption process (Ho & Hong, 2011; Lai, Liu, Li, Di, & Cai, 2010) . When rats were given SAB 300 mg kg −1 , the tissue concentrations (ordered from highest to lowest) were as follows: liver, lung, kidney, spleen, and brain, with no SAB detected in the heart . SAB can cross the blood-brain barrier, but its concentration in the brain is very low. SAB may also be combined with certain brain proteins . Li et al. reported that after intravenous administration of SAB, the area under the receiver operating characteristic curve (AUROC) values of SAB in the tissues of rats were as follows: kidney > lung > liver > heart > spleen > brain (Li et al., 2007) . SAB conventional and long-circulating liposomes have succeeded in prolonging the retention time and increasing the level of SAB distributed in certain tissues, such as the liver, kidney, and brain (Pi et al., 2015) . All of these studies showed that the liver is an important target organ of SAB in the body.
SAB is mainly methylated by catechol O-methyltransferase (COMT) in the rat liver and kidney, and it acts as a weak COMT inhibitor in rats (Qi et al., 2015) . However, how SAB passes through liver cell membranes and accumulates in hepatocytes is currently unclear.
A study showed that when rifampicin was administered intravenously 15 min prior to SAB, the area under the curve (AUC 0-t ) and maximum (or peak) serum concentration (C max ) values in the SAB group were significantly higher than those in the control group, while the total clearance (CL) and bile CL values significantly decreased (Zhao et al., 2012) .
The influence of rifampicin on the pharmacokinetics of SAB may be attributed to the inhibition of organic anion transporting polypeptide (OATP)-mediated influx (Zhao et al., 2012) , but further study of this mechanism is needed.
OATPs (Oatps; SLCO/Slco) represent an important family of drug uptake transporters that mediate the cellular uptake of a broad range of substrates including numerous drugs (Lee, Leake, Kim, & Ho, 2017) , and among these family members, OATP1B1 is predominantly expressed at the basolateral membranes of hepatocytes in the liver and have been implicated to play key roles in the hepatic uptake and plasma clearance of a number of drug substrates and toxins (Hagenbuch & Gui, 2008; .
In this study, we first explored the uptake features of SAB in human hepatoma cells (HepG2 we divided our experiments into six groups and added a series of SAB concentrations (0, 4, 8, 16, 32 , and 64 μM) in DMEM. After 10 min of incubation, DMEM was removed, and the cells were washed three times with phosphate buffered saline (1 × PBS). Then, 0.5 ml of sterile water was added to the cells, and plates were placed in an ultra-low temperature freezer at −80°C three times.
The cell lysate was collected and centrifuged at 11,000 rpm for The protein concentration of each sample was determined using the bicinchoninic acid (BCA) Protein Assay Kit.
| Effect of rifampin on the uptake of SAB and the effects of SAB on HepG2 uptake of pitavastatin
To study the effect of rifampin on the uptake of SAB in HepG2,
we added a series of concentrations of rifampin (0, 3.2 | Effect of rifampicin on the uptake of SAB and the effect of SAB on the uptake of pitavastatin in HepG2
As rifampicin concentrations increased, the observed inhibitory effect on the uptake of SAB in HepG2 cells became increasingly obvious, with an IC50 value of 5.85 ± 1.70 μM. 95% CI of the IC50 was ) in HepG2. Transport measured in cells with the salvianolic acid B alone was set to 100%, and the effect of the rifampicin was compared with this value (ordinate). IC50 value was 5.85 ± 1.70 μM and 95% CI of the IC50 was 3.95-7.75 μM. Results are presented as mean ± SD (n = 3). (b) Uptake of pitavastatin (5 μM) in HepG2 was measured in the absence or presence of the salvianolic acid B (2, 6, 18, 54, and 108 μM). Transport measured in cells with the pitavastatin alone was set to 100%, and the effect of the salvianolic acid B was compared with this value (ordinate). IC50 value for SAB was 27.67 ± 1.90 μM and 95% CI of the IC50 was 25.47-29.87 μM.
Results are presented as mean ± SD (n = 3) from the result of western blot, we could conclude that there was no obvious difference of OATP1B1 expression when OATP1B1-HEK239T cells were treatment with different concentrations of salvianolic acid B (0, 4, 8, and 16 μM) for 4 h (as shown in Figure 5 c). Therefore, it seems that SAB cannot inhibit or induce the expression of OATP1B1.
| DISCUSSION
SAB is an effective water-soluble component of S. miltiorrhiza. SAB has many pharmacological activities, such as myocardial protection, heart protection, antifibrosis, and antitumour activities. SAB has a high concentration in the liver (Wang, Kong, Jin, Chen, & Dong, 2015; Xu et al., 2007) , but the mechanism of its distribution in the liver remains unclear. Therefore, exploring the liver transport mechanism of SAB is important to investigate the pharmacological activity of SAB and its potential clinical application in future drug development.
Our previous study demonstrated that Danshensu, the metabolic component of SAB, acts as a potential competitive inhibitor of OATP1B1 and could affect the OATP1B1-mediated transport of rosuvastatin in the liver (Wen et al., 2016) . Other researchers discovered that the OATP inhibitor rifampicin could affect the pharmacokinetics of SAB, and Cmax and AUC were significantly increased with the addition of rifampicin, while the clearance rate of CL was significantly decreased (Zhao et al., 2012) . SAB, the main water-soluble component of S. miltiorrhiza, has anion characteristics. Therefore, the transport of SAB in the liver may be closely related to OATP. Presently, there are no relevant studies of the liver transport mechanism of SAB. OATP1B1 is a member of the OATP1B family. OATP1B1 is specifically expressed in the basolateral (sinusoidal) plasma membrane of liver cells and is involved in the transport of many drugs in the liver. Moreover, OATP1B1 has a homologous transporter, OATP1B2, in rats (Hua, Hua, Nan, Jiang, & Yan, 2014; .
Modern pharmacokinetic studies have shown that in addition to metabolic enzymes, transporters are a key factor for drug treatment in vivo and play an important role in drug absorption, elimination, and tissue distribution. Because SAB is mainly metabolised by the liver (Liu et al., 2016) , understanding the mechanism of liver uptake and transport of SAB is important for the study of its pharmacological action and avoiding drug-drug interactions.
In our studies, we first explored the uptake characteristics of SAB in HepG2 cells and found that with an increase in SAB, the uptake of SAB by cells increased. When the concentration of SAB was 32 μM, the SAB uptake by cells became saturated. The Vmax of SAB uptake was 21.28 ± 2.06 pmol mg −1 per protein min −1 and 28.47 ± 7.36 μM. Rifampicin acts as an inducer of P-glycoprotein and multidrug resistance-associated Protein 2; as an inhibitor of OATP, it could inhibit the uptake of SAB in HepG2 cells (Fattinger, Cattori, Hagenbueh, Meier, & Stieger, 2000; Fromm et al., 2000) .
With increasing rifampicin concentrations, the inhibitory effect on the uptake of SAB in HepG2 cells became more intense. The mechanism for this inhibitory effect may be closely related to OATPs;
however, the member of the OATP family involved in this process cannot be confirmed. Next, we explored whether SAB influenced the uptake of OATP1B1 substrates (such as pitavastatin) in HepG2.
As a result, the uptake of pitavastatin in HepG2 changed with varying SAB concentrations. When the concentration of SAB was 18-108 μM, the uptake of pitavastatin in HepG2 decreased significantly. SAB may act as an inhibitor of OATP1B1, causing a decrease in the uptake of pitavastatin in HepG2. SAB may also be a substrate of OATP1B1. Therefore, we could confirm that SAB was a substrate of OATP1B1
and that OATP1B1 mediated the transport of SAB in hepatic cells.
Because an increasing number of drugs or chemical substances have been identified as substrates of OATP1B1, it is necessary to focus on the drug-drug interactions between SAB, and these drugs or chemical substances when traditional Chinese medicine that contains SAB is applied in the clinic.
Finally, we explored the effect of SAB on the expression of OATP1B1. The total protein expression in OATP1B1-HEK239 cells was higher than that in EGFP-HEK293 cells when SAB was added to incubate about 2 or 4 h. But from the result of western blot, we could conclude that there was no obvious difference of OATP1B1 expression when OATP1B1-HEK239T cells were treatment with different concentrations of salvianolic acid B. Therefore, SAB may not induce or inhibit the expression of OATP1B1.
| CONCLUSIONS
In conclusion, this study was the first to investigate the mechanisms of SAB uptake in liver cells in vitro. The results indicated that OATP1B1
played an important role in this process. In addition, other influx or efflux transporters cannot be excluded from involvement in the transport process of SAB in liver cells. 
